Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 202000683 | Other Identifier | UMCG |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will evaluate if the Groningen Anti-Inflammatory Diet and the ileocolonic delivery of vitamin B2, B3 and C can positively influence the course of Crohn's disease and can positively alter the gut microbiome of Crohn's disease patients as well as healthy volunteers.
It is becoming increasingly more well known that diet and the microbiome have a pivotal role in the development and course of inflammatory bowel diseases (IBD). Strict exclusive enteral nutrition (EEN) can induce remission in Crohn's Disease (CD) and is the standard treatment in paediatric CD. Implementing a restrictive diet in adults is difficult; adult patients do not tend to adhere to EEN. Recently, the CD-exclusion diet (CDED) combined with partial enteral nutrition demonstrated to be effective in CD-patients with flares.
Additionally, accumulating evidence suggests that intake of vitamins can influence disease course, mainly by beneficially modulating the gut microbiota and gut redox potential, especially if the vitamins can be delivered to the colon.
Nevertheless, no dietary guidelines are available to physicians and patients. Due to complaints of certain foods and patients' eagerness to postpone new flares, patients start experimenting with their food. As patients with CD are already often malnourished, this poorly substantiated experimenting puts them even more at risk for malnutrition and could have a potential negative effect on their disease outcomes. Next, quality of life of patients decreases and healthcare costs will rise. Therefore, both patients and physicians are in desperate need of evidence for an anti-inflammatory dietary advice in CD. As compliance to a diet increases when they are supported by family members, their household members will also be asked to participate in the study. Simultaneously studying their healthy family members will also provide information of the effect of this anti-inflammatory diet or intake of lieocolonic-delivered vitamins on their microbiome and markers of inflammation and oxidative stress.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Groningen Anti-Inflammatory Diet (GrAID) | Experimental | Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. |
|
| ColoVit capsule | Experimental | 2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery |
|
| Placebo capsule | Placebo Comparator | 2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Groningen Anti-Inflammatory Diet (GrAID) | Other | Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in faecal calprotectin | Primary outcome for CD patients | Faeces sample collection at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months |
| Change in microbiome composition measured by metagenomic sequencing- based profiles | Primary outcome for healthy volunteers and CD patients | Faeces sample collection at 3 time points: At baseline (0 months), after 3 months, after 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| The number of flares (defined as faecal calprotectin >200 μg/g and Crohn's Disease Activity Index (CDAI) ≥220 points) | Secondary outcome for CD patients | Faeces sample collection and CDAI score determination at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months |
| Improvements of Quality of life scores as assessed by Inflammatory Bowel Disease Questionnaire (Score range of 32-224, The higher the score the higher the Quality of Life) |
Not provided
Inclusion Criteria CD patients:
Inclusion Criteria healthy volunteers:
Exclusion Criteria CD patients:
Exclusion Criteria healthy subjects:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gerard Dijkstra, MD PhD | Contact | +31 050 3612620 | gerard.dijkstra@umcg.nl |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Medical Center Groningen | Recruiting | Groningen | 9713GZ | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36918234 | Derived | Otten AT, Peters V, Barth I, Stevens CL, Bourgonje AR, Frijlink HW, Harmsen HJM, Rehman A, Campmans-Kuijpers MJE, Dijkstra G. Effects of ileocolonic delivered vitamin B2, B3 and C (ColoVit) or the Groningen anti-inflammatory diet on disease course and microbiome of patients with Crohn's disease (VITA-GrAID study): a protocol for a randomised and partially blinded trial. BMJ Open. 2023 Mar 14;13(3):e069654. doi: 10.1136/bmjopen-2022-069654. |
Not provided
Not provided
There is no plan to make individual participant data available to other researchers outside of the study team.
Not provided
Not provided
Not provided
Not provided
Not provided
Randomized, partly blinded, multicenter clinical food trial
Not provided
Not provided
Not provided
|
| ColoVit capsule | Dietary Supplement | Vitamin B2/B3/C supplement in a ColoPulse-coated capsule |
|
| ColoPulse-placebo capsule | Other | A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit |
|
Secondary outcome for CD patients |
| Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months |
| Improvements of Quality of life scores as assessed Food Related Quality of Life Questionnaire (Score range of 29-145, The higher the score the higher the Food related-Quality of Life) | Secondary outcome for CD patients and healthy volunteers | Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months |
| Adherence to the dietary interventions as assessed by a Dietary Compliance Questionnaire | Secondary outcome for CD patients and healthy volunteers | Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months |
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D015212 | Inflammatory Bowel Diseases |
| ID | Term |
|---|---|
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided